157 related articles for article (PubMed ID: 18551039)
1. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.
Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH
Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039
[TBL] [Abstract][Full Text] [Related]
2. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation.
van Noord C; Aarnoudse AJ; Eijgelsheim M; Sturkenboom MC; Straus SM; Hofman A; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
Pharmacogenet Genomics; 2009 Apr; 19(4):260-6. PubMed ID: 19247217
[TBL] [Abstract][Full Text] [Related]
3. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study.
Aarnoudse AJ; Newton-Cheh C; de Bakker PI; Straus SM; Kors JA; Hofman A; Uitterlinden AG; Witteman JC; Stricker BH
Circulation; 2007 Jul; 116(1):10-6. PubMed ID: 17576865
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
6. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
7. SNP association and sequence analysis of the NOS1AP gene in SIDS.
Osawa M; Kimura R; Hasegawa I; Mukasa N; Satoh F
Leg Med (Tokyo); 2009 Apr; 11 Suppl 1():S307-8. PubMed ID: 19289301
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
9. A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers.
Becker ML; Visser LE; Newton-Cheh C; Hofman A; Uitterlinden AG; Witteman JC; Stricker BH
Br J Clin Pharmacol; 2009 Jan; 67(1):61-7. PubMed ID: 19076153
[TBL] [Abstract][Full Text] [Related]
10. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides.
Mannucci E; Monami M; Masotti G; Marchionni N
Diabetes Metab Res Rev; 2004; 20(1):44-7. PubMed ID: 14737744
[TBL] [Abstract][Full Text] [Related]
11. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
Horsdal HT; Mehnert F; Rungby J; Johnsen SP
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
[TBL] [Abstract][Full Text] [Related]
12. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
Holstein A; Hahn M; Stumvoll M; Kovacs P
Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
[TBL] [Abstract][Full Text] [Related]
13. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
14. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
15. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
[TBL] [Abstract][Full Text] [Related]
16. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
17. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Johnson JA; Simpson SH; Toth EL; Majumdar SR
Diabet Med; 2005 Apr; 22(4):497-502. PubMed ID: 15787679
[TBL] [Abstract][Full Text] [Related]
18. Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock.
Nakada TA; Russell JA; Boyd JH; McLaughlin L; Nakada E; Thair SA; Hirasawa H; Oda S; Walley KR
Crit Care Med; 2011 Jul; 39(7):1641-8. PubMed ID: 21423001
[TBL] [Abstract][Full Text] [Related]
19. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.
Pearson ER; Donnelly LA; Kimber C; Whitley A; Doney AS; McCarthy MI; Hattersley AT; Morris AD; Palmer CN
Diabetes; 2007 Aug; 56(8):2178-82. PubMed ID: 17519421
[TBL] [Abstract][Full Text] [Related]
20. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
